Switch to a Second JAK Inhibitor Helpful in UC

TOPLINE: Switching to a second-line Janus kinase (JAK) inhibitor resulted in steroid-free clinical remission in about half of the patients with active ulcerative colitis (UC) after induction; compared with filgotinib, upadacitinib as a second JAK inhibitor was independently associated with the improved outcome. METHODOLOGY: Researchers conducted a retrospective observational cohort study across 28 Belgian and …